Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Medical College of Wisconsin
In this study the treating physicians will deliver a high dose of radiation to pelvic lymph nodes of 56 Gy (Gy/Gray = measure of amount of radiation) and at the same time give a boost (additional) radiation to the prostate itself (to 70 Gy). The study will evaluate the response of the cancer and side effects of radiation to pelvic lymph nodes and to the prostate.
It is hoped that these newer technologies will:
1. allow a higher daily dose of radiation to the tumor and pelvic nodes
2. avoid nearby normal tissue and organs like the rectum and bladder
3. prevent the cancer from spreading or coming back
Age
18–any
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
Histologically confirmed, adenocarcinoma of the prostate
T1-2N0M0 with risk of pelvic lymph nodes involvement \>25% by Roach formula \[(2/3xPSA) + (Gleason Score - 6)x10\], or any T3-4N0M0
Karnofsky Performance Scale \> 70.
Prostate tumor biopsy grading by Gleason score classification is mandatory prior to registration.
No prior pelvic or prostate radiation or chemotherapy for any reason; induction hormonal therapy prior to registration is acceptable.
Patients must sign a study-specific consent form prior to registration.
No evidence of distant metastases (Bone scanning)
You may not be if
Clinical or pathological evidence of distant metastases (M1).
